8 registrations that name shatavari as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 8 registrations
Status
7US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 8 registrations
RecruitingNCT07834463
Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)
No phase
India Glycols Ltd
About 100 people
Started Sep 1, 2026
In plain words A study of shatavari in female participants 45 to 60, run by India Glycols Ltd. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 45 to 60. Conditions: Menopause; Hot Flashes.
Female subjects aged 45-60 years at screening.
Post-menopausal status, defined as no menstrual period for at least 12 months, graded as post-menopausal per STRAW classification (not due to pregnancy, lactation, or medical/surgical causes).
Menopause Rating Scale (MRS) score > 9 at screening.
Average frequency of hot flashes >= 3 per day for at least 7 consecutive days prior to screening.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Shatavari (Asparagus racemosus) Extract; Placebo
Registered summary
This study will evaluate whether an 8-week course of a standardized herbal extract containing Shatavari and natural bio-enhancer ingredients can reduce menopausal symptoms in post-menopausal women. The study will compare the herbal extract with a matching placebo. Approximately 100 women aged 45 to 60 years with menopausal symptoms will be enrolled, with approximately 80 expected to complete the study. Participants will take one study product daily for 8 weeks. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07441083
Efficacy and Safety of Shatavari Root Extract in Women's Sexual Wellness
No phase
SF Research Institute, Inc.
About 60 people
Starts Apr 29, 2026 (estimated)
In plain words A study of shatavari in female participants 20 to 50, run by SF Research Institute, Inc.. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 50; healthy volunteers accepted. Conditions: Sexual Wellness; Women Health.
Women between 20 to 50 years of age.
Sexually active, attempting sexual activity, or experiencing concerns related to sexual desire or function, with a partner and have a FSFI total score ≤ 26.55.
Have a PSS-10 score of ≥ 14 at screening.
Women presenting with signs and symptoms suggestive of stress (e.g., difficulty, concentrating, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, worry, sweating, mental confusion, etc.).
5 more inclusion criteria and the exclusion criteria are on the listing.
This randomized, double-blind, placebo-controlled clinical study is designed to evaluate the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract (SRI-81) in improving women's sexual wellness. Sexual wellness is assessed as a multidimensional construct encompassing sexual function, sexual distress, sexual satisfaction, perceived stress, quality of life, and physiological stress markers. Participants will receive either Shatavari root extract or placebo for 12 weeks, with assessments conducted at baseline and follow-up visits.
Where, as registered
1 US site in 1 state.
RecruitingNCT06716554
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
No phase
SF Research Institute, Inc.
About 51 people
Started Oct 26, 2024
In plain words A study of shatavari in female participants 45 to 55, run by SF Research Institute, Inc.. It plans to enroll about 51 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 45 to 55; healthy volunteers accepted. Conditions: Menopause; Hot Flashes; Mood.
Menopausal women aged 45 to 65 years with intact uterus and ovaries.
Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months, or reported menopause for at least 60 days
Females with complaints of menopausal symptoms, e.g., hot flash, insomnia, migraine, easy irritation, etc.
Body mass index 18-35 kg/m2
4 more inclusion criteria and the exclusion criteria are on the listing.
This is a Multi-center, Multi-national, Prospective, Randomized, Double-Blind, Placebo- Controlled three arm study to evaluate the efficacy and safety of Shatavari for the treatment of Menopausal symptoms in Women. Participants will be randomized to either one of the three treatment arms.Participants will then be asked to either take one capsule containing Shatavari or Shatavari + Ashwagandha or Placebo orally once daily in the morning after breakfast with a glass of water for 8 weeks. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07861295
Satavari and Ashoka for Menopause (SAM) Study
No phase
Vidya USA Corporation
About 50 people
Started Oct 1, 2025
In plain words A study of shatavari in female participants 40 to 65, run by Vidya USA Corporation. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 65. Conditions: Menopause.
Females aged 40-65 years.
Postmenopausal women in good overall health and fulfilling menopausal criteria set at the MRS score more than 5.
Subjects had experienced absence of regular menstrual cycle for at least 3 months.
Willingness to sign consent, follow protocols and regimen intake, as well as maintain normal physical activity and follow study procedures.
The exclusion criteria are on the listing.
What it tests, as registered
Ashoka Bark and Shatavari; Placebo
Registered summary
This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07441096
Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women
No phase
SF Research Institute, Inc.
About 60 people
Starts Mar 20, 2026 (estimated)
In plain words A study of shatavari in female participants 18 to 40, run by SF Research Institute, Inc.. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40; healthy volunteers accepted. Conditions: Premenstrual Syndrome; Women Health.
Healthy women aged 18-40 years with intact uterus and ovaries.
Females with complaints of experiencing mild to moderate PMS confirmed by one baseline cycle using the DRSP.
PSST sores consistent with PMS and not meeting criteria for severe PMS or PMDD.
Body mass index 18-35 kg/m2.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Shatavari Root Extract; Placebo Capsule
Registered summary
Premenstrual syndrome (PMS) is a common condition that affects women of reproductive age and is associated with emotional, physical, and behavioral symptoms such as mood swings, irritability, stress, sleep problems, fatigue, and abdominal discomfort. These symptoms typically occur during the days leading up to menstruation and may interfere with daily activities and overall quality of life. This study is designed to evaluate the efficacy and safety of Shatavari (Asparagus racemosus) root extract compared with placebo in women with mild to moderate PMS. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07441109
Shatavari Root Extract for Perimenopausal Symptoms
No phase
SF Research Institute, Inc.
About 60 people
Starts Mar 11, 2026 (estimated)
In plain words A study of shatavari in female participants 40 to 45, run by SF Research Institute, Inc.. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 45; healthy volunteers accepted. Conditions: Perimenopause; Women Health.
Menopausal women aged >40 to 45 years with intact uterus and ovaries.
Participants who complained of irregular menstrual cycle in the past 12 months, with a forward or postpone of a cycle more 7 days. At least 2 cycles were missing during the past 12 months or reported menopause for at least 60 days.
Females with complaints of at least two of the menopausal symptoms, e.g., hot flashes, night sweats, mood swings, sleep disturbance, breast tenderness
Body mass index 18-35 kg/m2
4 more inclusion criteria and the exclusion criteria are on the listing.
This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06939868
Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women
No phase
Jacksonville University
About 44 people
Starts May 1, 2025 (estimated)
In plain words A study of shatavari in female participants 40 to 60, run by Jacksonville University. It plans to enroll about 44 people at 1 US site.
Menopause Rating Scale score: (a) GE 14 and (b) score of 3 or 4 (severe to very severe) for hot flashes (Blumel et al., 2018).
The exclusion criteria are on the listing.
What it tests, as registered
Shatavari Root Extract, oral capsule
Registered summary
The goal of this clinical trial is to learn if a daily nutritional supplement can reduce hot flashes and other menopausal symptoms in postmenopausal women. The main questions this study aims to answer are: Does the supplement reduce the number and severity of daily hot flashes? Does it improve other common menopausal symptoms? Researchers will compare the supplement to a placebo (a look-alike capsule with no active ingredients) to see if it helps manage symptoms during menopause. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07853560
Study to Investigate Asparagus Racemosus Extract (Shaktiva™) for Psychological Symptoms in Perimenopausal Women
No phase
Liaquat University of Medical & Health Sciences
About 100 people
Starts Dec 1, 2026 (estimated)
In plain words A study of shatavari in female participants 40 to 55, run by Liaquat University of Medical & Health Sciences. It plans to enroll about 100 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 40 to 55. Conditions: Perimenopausal Disorder.
Female participants aged 40-55 years.
Meet STRAW+10 criteria for early (Stage -2) or late (Stage -1) menopausal transition, defined as either a persistent change in menstrual-cycle length of ≥7 days during the preceding 12 months or an interval of amenorrhoea of ≥60 days but…
Have experienced at least one menstrual period within the preceding 12 months.
Mild-to-moderate symptoms in at least two of the three DASS-42 domains (Depression, Anxiety, and Stress) at screening, according to predefined DASS-42 severity thresholds.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Asparagus racemosus Extract (Shaktiva™); Placebo
Registered summary
Perimenopause is commonly associated with psychological symptoms, including low mood, anxiety, and stress, which can negatively affect wellbeing and quality of life. This study will investigate whether Shaktiva™, a standardised extract of Asparagus racemosus (Shatavari), can improve psychological symptoms in perimenopausal women. This is an 8-week, multicentre, randomized, double-blind, placebo-controlled clinical trial involving 100 perimenopausal women. Participants will be randomly assigned to receive either Shaktiva™ 300 mg once daily or a matching placebo. The full summary is on the listing.